Richard Goodwin joins DTR Advisory Board
Posted: 11 October 2017 | Steve Bremer (Drug Target Review) | No comments yet
Dr Goodwin is the latest top-level scientist to join DTR’s advisory board
New DTR Advisory Board member Richard Goodwin
Richard Goodwin, Principal Scientist, Drug Safety and Metabolism at AstraZeneca, has joined the Editorial Advisory Board for Drug Target Review.
Dr Goodwin has been with AstraZeneca since 2011 and leads the mass spectrometry imaging team. The group uses MS imaging to investigate the efficacy and safety of new medicines and supports projects from early discovery through to the clinic.
Prior to starting with AstraZeneca in the UK, Dr Goodwin was an AstraZeneca funded postdoctoral researcher at Uppsala, Sweden. He received his PhD from University of Edinburgh in 2006, followed by a postdoctoral position at University of Glasgow. He collaborates with a wide range of academic researchers developing and employing molecular imaging technologies.
Drug Target Review has just announced the launch of its NEW and EXCLUSIVE report examining the evolution of AI and informatics in drug discovery and development.
In this 63 page in-depth report, experts and researchers explore the key benefits of AI and informatics processes, reveal where the challenges lie for the implementation of AI and how they see the use of these technologies streamlining workflows in the future.
Also featured are exclusive interviews with leading scientists from AstraZeneca, Auransa, PolarisQB and Chalmers University of Technology.
Related topics
Imaging, Mass Spectrometry, Molecular Modelling
Related organisations
AstraZeneca
Related people
Richard Goodwin
